首页> 外文期刊>Firat Tip Dergisi >Comparison of Effects of Atorvastatin and Fenofibrate on Plasma Homocysteine, Folic Acid and Vitamin B12 Levels in Patients With Mixed Hyperlipidemia
【24h】

Comparison of Effects of Atorvastatin and Fenofibrate on Plasma Homocysteine, Folic Acid and Vitamin B12 Levels in Patients With Mixed Hyperlipidemia

机译:阿托伐他汀和非诺贝特对混合性高脂血症患者血浆同型半胱氨酸,叶酸和维生素B12水平影响的比较

获取原文
       

摘要

Summary Objectives: Hyperhomocysteinemia is an independent cardiovascular risk factor. Lipid lowering agents such as fenofibrate have been reported to elevate plasma homocysteine levels. Atorvastatin is another kind of lipid lowering agent and there is not enough study investigating its effects on plasma homocysteine. In the present study we aimed to compare the effects of atorvastatin and fenofibrate on plasma homocysteine, folic acid and vitamin B12 levels.Materials and Methods: Total of 43 patients were randomized into one of 2 groups: One of them (n=20) treated with atorvastatin, other (n=23) with fenofibrate for 3 months. After 1 and 3 months of treatment with these drugs, blood samples were collected and plasma lipids, folic acid, vitamin B12 and homocysteine levels were determined.Results: Both of the lipid lowering agents significantly decreased plasma lipid levels. Atorvastatin group showed a significant reduction in total cholesterol and LDL-C than those in fenofibrate group. On the other hand, fenofibrate caused a greater reduction in triglyceride levels compared to the atorvastatin. There was no change in plasma folic acid and vitamin B12 levels after treatment with both of these hypolipidemic drugs. There was a significant increase in homocysteine levels after treatment with fenofibrate and atorvastatin, although fenofibrate was more effective than atorvastatin (36 and 15% respectively).Conclusions: We conclude that increases in plasma homocysteine levels are a result of the known impairment of renal function caused by fenofibrate and a result of impairment of liver function caused by atorvastatin.?2006, Fırat üniversitesi, Tıp Fakültesi Top
机译:摘要目标:高同型半胱氨酸血症是独立的心血管危险因素。据报道降脂剂如非诺贝特可升高血浆同型半胱氨酸水平。阿托伐他汀是另一种降脂剂,目前尚无足够的研究研究其对血浆同型半胱氨酸的影响。在本研究中,我们旨在比较阿托伐他汀和非诺贝特对血浆同型半胱氨酸,叶酸和维生素B12水平的影响。材料与方法:将43例患者随机分为两组:一组(n = 20)与阿托伐他汀合用,其他(n = 23)与非诺贝特合用3个月。用这些药物治疗1个月和3个月后,收集血液样本,测定血浆脂质,叶酸,维生素B12和高半胱氨酸水平。结果:两种降脂剂均显着降低了血浆脂质水平。阿托伐他汀组的总胆固醇和低密度脂蛋白胆固醇明显低于非诺贝特组。另一方面,与阿托伐他汀相比,非诺贝特引起的甘油三酸酯水平降低更大。用这两种降血脂药治疗后,血浆叶酸和维生素B12的含量没有变化。尽管非诺贝特比阿托伐他汀更有效(分别为36%和15%),但非诺贝特和阿托伐他汀治疗后同型半胱氨酸水平显着增加。结论:我们得出结论,血浆同型半胱氨酸水平升高是已知肾功能受损的结果由非诺贝特引起和阿托伐他汀引起肝功能损害。?2006,Fıratüniversitesi,TıpFakültesi

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号